A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
BACKGROUND: Organ transplant is a rapidly growing area of medicine, with over 42,800 organ transplants occurring in 2022.[1] Obesity complicates the transplant surgery process; historically, the only available treatment for patients with both severe…
INTRODUCTION: Tirzepatide, a dual GIP/GLP-1 receptor agonist, is highly effective in reducing body weight and improving glucometabolic outcomes. However, most clinical trials have overlooked the role of diet quality, leaving unclear whether lifestyle…
The global rise in obesity has accelerated both clinical and pharmaceutical innovation in antiobesity pharmacotherapy. This narrative review synthesizes current evidence on Food and Drug Administration-approved medications and emerging investigationa…
BACKGRUOUND: Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide. METHODS: RCTs inv…
INTRODUCTION: Traditionally, obstructive sleep apnea (OSA) management has focused on continuous positive airway pressure therapy, oral appliances, and in some cases, surgical interventions. However, these treatments do not directly address the underl…
BACKGROUND: GLP-1 medicines (e.g. Semaglutide; Tirzepatide) are diabetes medicines that have recently been approved for weight loss purposes. These drugs are increasingly common, with many users accessing these medicines for off-label lifestyle-orien…
Tirzepatide induces weight reduction but the underlying mechanisms are unknown. This 6-week phase 1 study investigated early effects of tirzepatide on energy intake. Male and female adults without diabetes (n = 114) and a body mass index from 27 to 5…
BACKGROUND: Glucagon-like peptide-1 receptor agonists and their analogues have emerged as effective pharmacotherapies for obesity. OBJECTIVE: To assess the short-term cost-effectiveness of subcutaneous tirzepatide, semaglutide, liraglutide, and oral…
Among newer classes of drugs for type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are incretin-based agents that lower both blood sugar levels and promote weight loss. They do so by activating pancreatic GLP-1 re…
BACKGROUND: Obesity imposes a heavy burden on healthcare systems and society. Despite various treatment options, choosing cost-effective pharmacological interventions remains a key concern for health policymakers. This study systematically reviews ec…
BACKGROUND Tirzepatide is effective for glycemic control and weight management in type 2 diabetes and obesity. Clinical trials have demonstrated tirzepatide's lower risk of acute kidney injury (AKI) compared with existing glucagon-like peptide-1 rece…
INTRODUCTION: Tirzepatide is one of the commonly used combined glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonists for weight loss in recent years. There are significant advantages of these medications for…
INTRODUCTION: To evaluate counterregulatory hormonal responses during a hypoglycemic clamp with tirzepatide. METHODS: Participants with type 2 diabetes (N=42) were randomized to tirzepatide (15 mg) or placebo for 12 weeks in a crossover design, with…
Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and is a promising therapeutic option for type 2 diabetes mellitus (T2DM). Nevertheless, its effect and underlying mecha…
OBJECTIVE: People with early-onset obesity (diagnosed at age < 25 years) may present with more cardiometabolic abnormalities and obesity-related complications. This post hoc analysis assessed baseline characteristics and body weight (BW) changes with…
In the management of hypertension, only limited advances have been made over the past decades. Recent studies highlight the potential of next-generation incretin-based therapeutics, such as GLP-1 RAs (glucagon-like peptide-1 receptor agonists) like s…
Fifteen to forty% of patients experience recurrent weight gain (RWG) after metabolic bariatric surgery (MBS). Glucagon-like peptide receptor agonists (GLP-1 RAs) are effective treatments for obesity in nonsurgical patients. To assess the effects of s…